Please login to the form below
Valneva
This page shows the latest Valneva news and features for those working in and with pharma, biotech and healthcare.
Valneva to compare its COVID-19 vaccine candidate to AstraZeneca’s jab
Phase 3 trial will test Valneva’s vaccine candidate against Vaxzevria in approximately 4, 000 participants. ... VLA2001 uses the same manufacturing platform used by Valneva to create its licensed Japanese encephalitis vaccine, Ixiaro.
Latest news
-
UK orders 40 million additional doses of Valneva’s COVID-19 vaccine
The UK government has confirmed this, adding in a statement that Valneva started manufacturing doses of the vaccine last week. ... VLA2001 uses the same manufacturing platform used by Valneva to create its licensed Japanese encephalitis vaccine, Ixiaro.
-
Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
UK. Valneva’s vaccine candidate is made of inactivated whole virus particles of SARS-CoV-2, which causes COVID-19, with high S-protein density. ... VLA2001 uses the same manufacturing platform used by Valneva to create its licensed Japanese
-
Valneva launches phase 1/2 COVID-19 vaccine trials in the UK
VLA2001 uses the same manufacturing platform used by Valneva to create its licensed Japanese encephalitis vaccine, Ixiaro. ... the world, assuming the vaccine is safe and effective,” said Thomas Lingelbach, chief executive officer of Valneva.
-
Moderna expects to supply 125 million COVID-19 vaccine doses in Q1 2021
So far, the UK has secured access to COVID-19 vaccine candidates from AstraZeneca, BioNTech/Pfizer, Novavax, Valneva, GlaxoSmithKline/Sanofi Pasteur and Janssen, as well as Moderna.
-
Moderna and UK sign agreement for additional doses of COVID-19 vaccine
So far, the UK has secured access to potential COVID-19 vaccine candidates from AstraZeneca, BioNTech/Pfizer, Novavax, Valneva, GlaxoSmithKline/Sanofi Pasteur and Janssen, as well as Moderna.
UK orders 40 million additional doses of Valneva’s COVID-19 vaccine
Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
Moderna expects to supply 125 million COVID-19 vaccine doses in Q1 2021
More from news
Approximately 5 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Pharma deals during December 2012
The Vivalis shareholders will own 55 per cent of the new company called Valneva based in Lyon and the Intercell shareholders will obtain a 32 per cent premium for their
Pharma deals during December 2012
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Valneva expands management board
Appoints David Lawrence and Wolfgang Bender. Commercial stage biotech Valneva has appointed David Lawrence and Wolfgang Bender, a move that will strengthen the senior management team for future growth.
Valneva expands management board
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Management
-
Competitive Salary Offered
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Senior Medical Writer
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Account Executive
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Account Manager
-
Competitive Salary
-
Publications Director
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Associate Account Director
-
Competitive Salary
-
Medical Editor
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Bedrock Group
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
